The first-line effect of bortezomib-based therapy on clinical outcomes for Taiwanese patients with multiple myeloma

被引：0
|
作者：
Ho, C-L. [1 ]
Chen, J-H. [1 ]
机构：
[1] Triserv Gen Hosp, Natl Def Med Ctr, Dept Med, Taipei, Taiwan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1087P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
    Shijia Zhang
    Amit A. Kulkarni
    Beibei Xu
    Haitao Chu
    Taxiarchis Kourelis
    Ronald S. Go
    Michael L. Wang
    Veronika Bachanova
    Yucai Wang
    Blood Cancer Journal, 10
  • [32] Superior myeloma response with bortezomib-based regimen in multiple myeloma patients with renal impairment
    Bao, Li
    Lu, Jin
    Wang, Shihua
    Huang, Xiaojun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (03): : 6200 - 6209
  • [33] Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
    Zhang, Shijia
    Kulkarni, Amit A.
    Xu, Beibei
    Chu, Haitao
    Kourelis, Taxiarchis
    Go, Ronald S.
    Wang, Michael L.
    Bachanova, Veronika
    Wang, Yucai
    BLOOD CANCER JOURNAL, 2020, 10 (03)
  • [34] CLINICAL EXPERIENCE WITH FIRST-LINE VRD IN MULTIPLE MYELOMA DIAGNOSTIC PATIENTS
    De Miguel Llorente, D.
    Gil Perez, A.
    Diaz Morfa, M.
    Golbano Lopez, N.
    Vazquez Ramo, A.
    Guillen Lopez, H.
    Nuevo Lopez, I
    Perez Ortega, A.
    Arbeteta Juanis, J.
    Subira Perez, D.
    Morales Sanz, D.
    Garcia Ramirez, P.
    Santos Montero, A. B.
    Herrero Martin, S.
    HAEMATOLOGICA, 2019, 104 : 194 - 195
  • [35] First-line therapy with Bendamustine/Prednisone/Bortezomib (BPV) for non-transplant eligible symptomatic multiple myeloma patients
    Knauf, W.
    Dingeldein, G.
    Schlag, R.
    Welslau, M.
    Kunz, C.
    Moehler, T.
    Habermehl, C.
    Goldschmidt, H.
    Raab, M-S
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 188 - 188
  • [36] CLINICAL EXPERIENCE WITH FIRST-LINE VRD IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA
    De Miguel, Llorente Dunia
    Gil, Perez Angela
    Merchan, Munoz Beatriz
    Nuevo, Lopez Irene
    Perez, Ortega Alba
    Guillen, Garcia Helga
    Vazquez, Ramo Alejandro
    Subira, Perez Dolores
    Golbano, Lopez Nuria
    Santos, Montero Ana Belen
    Morales, Sanz Dolores
    Arbeteta, Juanis Jaime
    HAEMATOLOGICA, 2020, 105 : 150 - 151
  • [37] Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
    Kristian T. Andersen
    Maja Hinge
    Agoston Gyula Szabo
    Erik Segel
    Tina Ormstrup
    Paw C. Holdgaard
    Niels Pallisgaard
    Gitte Kerndrup
    Torben Plesner
    Clinical Hematology International, 2020, 2 (1) : 35 - 39
  • [38] Dramatic results seen in phase III front-line multiple myeloma trials of bortezomib-based therapy
    不详
    ONCOLOGY-NEW YORK, 2008, 22 (01): : 80 - 81
  • [39] BORTEZOMIB-BASED REGIMENS AS INDUCTION AND MAINTENANCE TREATMENT IN MULTIPLE MYELOMA (MM) PATIENTS NOT ELIGIBLE FOR AGGRESSIVE THERAPY
    Mazzone, C.
    Gentile, M.
    Vigna, E.
    Lucia, E.
    Lorio, C.
    Morelli, R.
    Bisconte, M. G.
    Gentile, C.
    Morabito, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 544 - 544
  • [40] Current standards for first-line therapy of multiple myeloma
    Jagannath, Sundar
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 : S207 - S214
12345